Osaka

Kobayashi Pharmaceutical, the Japanese company at the center of a supplement contamination scandal involving suspected deaths, is reportedly considering a potential buyout offer valued at more than ¥500 billion. The news puts the embattled Osaka-based drugmaker back in the spotlight, with attention on who might take over the firm and what it would mean for the company's future after the scandal damaged its reputation and finances.